Abstract

Surgical resection is considered a standard therapy for malignant melanoma (MM). However, it has not yet been established as an optimal treatment strategy for gynecological MMs, particularly owing to their very low incidence rates. We retrospectively analyzed clinical outcomes of carbon-ion radiotherapy (C-ion RT) for gynecological MMs. The eligibility criterion was the presence of histologically confirmed gynecological MM. Patients with pelvic or inguinal lymph node metastases were included, while those with distant metastases were excluded. The pelvic and inguinal lymph node regions were irradiated with up to 36 gray relative biological effectiveness (Gy (RBE)) followed by a gross tumor volume boost of up to 57.6 Gy (RBE) or 64 Gy (RBE) in 16 fractions over 4 weeks. Thirty-seven patients (median age: 71 years) were examined. In total, 22 patients had vaginal tumors, 12 had vulval tumors, and 3 had cervical uterine tumors. The median follow-up periods were 23 months (range: 5–103 months) for all patients and 53 months (range: 16–103 months) for survivors. Thirty of 37 patients (81%) achieved complete tumor disappearance. The 2-year local control, overall survival, and progression-free survival rates were 71%, 53%, and 29%, respectively. C-ion RT may be a definitive treatment option for patients with gynecological MM.

Highlights

  • Melanomas are malignant tumors arising from melanocytes

  • Two patients who had tumors of >60 mL were irradiated with a total dose of 64.0 gray relative biological effectiveness (Gy (RBE)) in 16 fractions, 35 patients were irradiated with a total dose of 57.6 Gy (RBE) in 16 fractions

  • This study was approved by our institutional review board—National Institute of Radiological Sciences Certified Review Board (Study ID: NIRS-18-001)—and was conducted in compliance with the Declaration of Helsinki

Read more

Summary

Introduction

Malignant melanoma (MM) is mostly of cutaneous origin, it can occur in various extracutaneous sites where melanocytes are present. The distribution of head and neck, anal/rectal, female genital tract, and urinary tract mucosal melanomas is 55.4%, Cancers 2019, 11, 482; doi:10.3390/cancers11040482 www.mdpi.com/journal/cancers. The prognosis for patients with gynecological MM is poorer than for those with cutaneous and other types of mucosal non-gynecologic MMs [5,6]. The 5-year overall survival (OS) rate in patients with head and neck, anal/rectal mucosal melanomas, and gynecological melanoma is 31.7%, 19.8%, and 11.4%, respectively [2]. En bloc excision with a safety margin is thought to be necessary for primary treatment; the median age of patients with gynecological MMs is higher than that of patients with other gynecological malignancies [2,3,4]. Even when the tumor is totally resected, the outcomes, in terms of local tumor control and long-term survival, are not satisfactory, show 5-year OS rates of 0–35% [2,3,5,8,9,10,11,12], and may result in postoperative physical and functional disabilities

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call